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Abstract
Introduction: Insulin resistance and type 2 diabetes mellitus (T2D) are associated with increased risk for cognitive
impairment, Alzheimer’s disease (AD) and vascular dementia. SORCS1 encodes a protein-sorting molecule genetically
linked to both T2D and AD. The association of SORCS1 with both AD and T2D is sexually dimorphic in humans, with
both disease associations showing more robust effects in females. Based on published evidence that manipulation of
the mouse genome combining multiple genes related to cerebral amyloidosis, to T2D, or both, might provide novel
mouse models with exacerbated amyloid and/or diabetes phenotypes, we assessed memory, glucose homeostasis, and
brain biochemistry and pathology in male and female wild-type, Sorcs1 -/-, APP/PSEN1, and Sorcs1 -/- X APP/PSEN1 mice.
Results: Male mice with either the APP/PSEN1 or Sorcs1 -/- genotype displayed earlier onset and persistent impairment
in both learning behavior and glucose homeostasis. Unlike prior examples in the literature, the behavioral and metabolic
abnormalities in male mice were not significantly exacerbated when the two disease model mice (Sorcs1 -/- models
T2D; APP/PSEN1 models AD) were crossed. However, female Sorcs1 -/- X APP/PSEN1 mice exhibited worse metabolic
dysfunction than Sorcs1 -/- knockout mice and worse memory than wild-type mice. The deletion of Sorcs1 from
APP/PSEN1 mutant mice led to no obvious changes in brain levels of total or oligomeric amyloid-beta (Aβ) peptide.
Conclusions: In general, unexpectedly, there was a trend for gene targeting of Sorcs1-/- to partially mitigate, not
exacerbate, the metabolic and amyloid pathologies. These results indicate that crossing AD model mice and T2D model
mice may not always cause exacerbation of both the amyloidosis phenotype and the metabolic phenotype and highlight
the unexpected pitfalls of creating mixed models of disease.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder and is the most common cause of dementia in the
elderly. There are approximately 34 million people afflicted
by AD worldwide and those numbers are expected to triple
over the next 40 years [5]. Type 2 diabetes mellitus (T2D)
increases the risk for dementia [15, 19, 42, 69]. Both T2D
and dementia are highly complex and share several features,
including impaired cognitive function, vascular dysfunction
and oxidative and inflammatory stress [15, 54]. Several
mechanisms have been proposed for this association, includ-
ing hypercholesterolemia, vasculopathic factors, and insulin
resistance [63]. Environmental factors, such as poor diet and
obesity are also known to increase the predisposition to T2D
and the risk for dementia [21]. The extent to which dementia
is due to AD or due to vascular dementia is an area of great
interest, and the pathology of dementia in T2D is usually
mixed [1, 43, 65].
Rare, early-onset familial Alzheimer’s disease (EOFAD) is
believed to begin with the accumulation of oligomeric forms
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of Aβ in the hippocampus and cortex. EOFAD is caused by
mutations in genes that directly influence Aβ metabolism,
most commonly the amyloid precursor protein (APP),
presenilin1 (PSEN1) or presenillin 2 (PSEN2). Mice express-
ing pathogenic mutant forms of human APP, PSEN, or both,
are mainstays of in vivo modeling of cerebral amyloidosis in
AD research. Of note, mice harboring EOFAD-pathogenic
mutations in both APP and PSEN1 have been observed
to develop insulin resistance (Ruiz et al. in press [56]).
Genetic studies of late-onset Alzheimer’s disease (LOAD)
point to a number of susceptibility genes, including several
that belong to one of three classes of molecules: the
apolipoprotein family (the most notable of which is apoli-
poprotein E [11, 59]; the low density lipoprotein receptor
(LDLR) family [22, 31]; and the vacuolar protein sorting-10
(VPS10) domain containing receptor family. The AD-
linked gene SORL1 belongs to both the LDLR family and
the VPS10-domain protein family, and a deficiency in SorL1
protein has been observed in the brains of patients suffering
from LOAD [12, 33, 55, 58, 60]. SorL1 has been demon-
strated to modulate Aβ generation via an interaction
with the core component of the retromer complex,
Vps35 [2, 39, 41, 61]. Human and animal studies in AD
have implicated Vps35 and other components of the
retromer complex [36, 64].
Multiple studies have demonstrated a connection be-
tween insulin resistance and T2D and increased risk for
cognitive impairment in humans [4, 13, 34, 62]. SORCS1,
another member of the Vps10 family, has been identified
as a potential risk factor for LOAD and is decreased in
AD brains [33]. SORCS1 resides at a quantitative trait
locus for T2D in mice and rats [10, 14] and has been
associated with both T1D and T2D [13]. Previously, we
initiated an investigation of the action of SorCS1 on
APP metabolism. We observed that endogenous murine
Aβ40 and 42 levels were increased in the brains of
female but not male Sorcs1 -/- mice, and this appeared to
involve an interaction mediated by the Vps35 retromer
complex [29]. This was especially interesting because the
genetic linkage to SORCS1 is sexually dimorphic with the
linkage to women being more robust. We hypothesized
that SORCS1 hypomorphism might contribute to the link
between insulin resistance and increased risk for cogni-
tive impairment in humans. A corollary of that hypoth-
esis is that dysregulation of SorCS1 may contribute to
both the Aβ disturbance underlying AD and the insulin/
glucose metabolism disturbance underlying DM, with
the two genes arranged either in parallel or in series.
Kebede et al. [23] demonstrated that Sorcs1-/- mice were
not overtly diabetic unless they were crossed with leptin
deficient (ob/ob) mice. In contemplating this result in the
context of the AD/T2D association with SORCS1, this
observation raised the possibility that Sorcs1-/- mice
crossed with AD model mice (here, APP/PSEN1 mice)
might manifest overt diabetes if stressed by the accumu-
lation of cerebral amyloid. Previous studies show that the
combination of a genetic proamyloidogenic phenotype
and potentially diabetogenic phenotype (induced by
either drug, diet, or genetic manipulations) can lead to
exacerbation of either the proamyloidogenic component
of the phenotype, the prodiabetogenic component of the
phenotype, or exacerbation of both components of the
phenotype [8, 18, 20, 38, 46, 51, 52, 66].
Here we report characterization of the memory, glucose
homeostasis and Aβ pathology in male and female wild-
type, Sorcs1 -/-, APP/PSEN1 and Sorcs1 -/- mice crossed
with APP/PSEN1 mice. Unexpectedly, there was a trend
for gene targeting of Sorcs1-/- to mitigate, not exacerbate,




Male and Female C57BL/6J wild-type (WT; n = 5–14/
group), Sorcs1 -/- (n = 10–16/group), APPSwe x PSEN1-
Δexon9 (APP/PSEN1; n = 5–11/group respectively) and
Sorcs1 -/- x APPSwe x PSEN1Δexon9 (Sorcs1 -/- x APP/
PSEN1; n = 5–9/group) were bred in the Icahn School of
Medicine at Mount Sinai Vivarium. We have previously
described the generation of the Sorcs1 -/- line [29]. All
animal studies were conducted in accordance with
National Institute of Health Guidelines for the Care and
Use of Experimental Animals and approved by the Insti-
tutional Animal Care and Use Committee at the Icahn
School of Medicine at Mount Sinai. Mice were kept in a
pathogen-free environment on a 12-h light/dark cycle,
and given ad libitum access to food and water. From
weaning until 6 months of age, cohorts were maintained
on standard rodent chow. Cohorts were subjected to
learning behavior assessment at 5 and 9 mo of age.
Cohorts were placed on a 60 % high fat diet (Diet 58Y1,
TestDiet, St. Louis, MO) at 6 mo of age for 4–12 weeks.
Mice were subjected to metabolic profiling prior to
starting the HFD at 4–5 mo of age then again after 4–12
weeks of HFD. All mice were weighed weekly. Following
final metabolic testing mice were anesthetized, and were
then perfused with ice-cold PBS. The brain was removed
and dissected into two hemispheres. One half was snap-
frozen on dry ice and stored at -80 °C for Aβ biochemistry.
The other half was post-fixed in 4 % PFA then cut into
30 μm coronal sections using a vibratome. Sections were
stored in PBS with 0.1 % NaAz until histological analyses.
Metabolic profiling
Body composition analyses
Total body fat and lean tissue were assessed using an
EchoMRI quantitative magnetic resonance system (Echo
Medical Systems) as previously described [57].
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Glucose tolerance test (GTT)
Mice were fasted for 5 h in a quiet testing room with
free access to water. Baseline fasted blood samples were
then taken via tail vein bleed to measure plasma insulin,
lipids, and branched-chain amino acids. Blood samples
were collected into EDTA coated microvette tubes and
placed on ice before being spun at 7 K for 6 min. Plasma
was then removed, snap frozen on dry ice and stored at
-80 °C until analyses. Mice were then injected intraperi-
toneally (i.p) with a 0.75 or 1.5 g/kg glucose solution
(Sigma Aldrich, St. Louis, MO). Blood glucose was mea-
sured via tail vein bleed immediately before the glucose
bolus then at 15, 30, 60, 90 and 120 min post injection.
Insulin tolerance test (ITT)
Mice were fasted for 5 h then given an i.p. injection of 1 or
2.5U/kg insulin (Humulin R, Lilly & Co., Indianapolis, IN)
solution. Blood glucose levels were measured prior to and
at 15, 30, 45, 60 and 90 min following the insulin bolus.
Behavioral testing
Mice were placed in the testing room 1 h prior to testing
to acclimatize to the room. All testing was completed
between 8 am-4 pm. All equipment was cleaned between
animals.
Novel object recognition (NOR)
Short-term non-associative memory based on the
natural exploration of novelty in mice was assessed in
the novel object recognition test as described [26].
Briefly, on day 1, the mouse was habituated in the NOR
arena (20 cm diameter) for 10 min. On day 2, the mouse
underwent the testing phase, composed of two stages.
During testing phase 1, the mouse was placed in the
arena and allowed to explore two identical unfamiliar
objects for 10 min. The mouse was then returned to its
home cage for an interval of 1 h. During this time, one
of the two objects the mouse was previously allowed to
explore was removed and replaced with a novel object.
During testing phase 2, the mouse was placed back into
the arena and allowed to explore the familiar object and
the novel object for 4 min. Trials were videotaped using
an overhead camera. The duration spent exploring the
objects was then measured using ANY-maze (Stoelting,
Wood Dale, IL). Exploration was defined as the amount
of time the mouse spent pointing their nose within 2 cm
of the object.
Y-maze spontaneous alternation (SA)
Short-term working was assessed in the Y-maze spontan-
eous alternation (SA) test as previously described [25] using
a black opaque Perspex Y-maze with 3 arms (A, B, and C)
each containing a visual cue (arm dimensions; 35x5x10 cm).
Briefly, each animal was placed in turn in arm A of the
Y-maze and allowed to explore for 8 min and the arm
entries made by each animal were recorded. Arm entry
was defined as having all 4 paws in the arm. Spontaneous
alternation was defined as a successive entry into 3 differ-
ent arms, on overlapping triplet sets. The percentage
number of alternations was calculated as the number of
actual alternations divided by the maximum number of
alternations (the total number of arm entries minus 2).
Biochemical and histological analyses
Plasma insulin, lipids, and branched-chain amino acid level
determination
Baseline, 1 and 3 months post HFD, levels of plasma
insulin were determined using a mouse insulin ELISA
kit (Mercodia, Sweden) according to the manufacturer’s
instruction. Glycerol and triglycerides were quantified
using a plasma triglyceride assay (Sigma Aldrich, St. Louis,
MO), which was modified to a 96-well plate format.
Non-esterified fatty acid (NEFA) levels were determined
using a NEFA kit from Wako (Wako Chemicals USA, Inc.
Richmond, VA) following the manufacturer’s instructions.
Plasma branched-chain amino acid (BCAA) levels were
determined using a fluorimetric assay as described [6].
Aβ assay
Hemibrains were processed via differential detergent
solubilization [40] to produce TBS-soluble, Triton-X-
soluble and formic-acid soluble Aβ fractions. Total Aβ
equals the sum of Aβ concentration in TBS-soluble,
Triton X-soluble and formic acid-soluble fractions. For
analysis of native oligomeric Aβ protein structure, 2–4 μl
native protein samples (from the TBS-soluble fraction)
were spotted onto activated/pre-wetted PVDF mem-
brane (0.22 μm; Millipore) and allowed to dry. Follow-
ing protein spotting, membranes were blocked for 1 h
at room temperature in 5 % w/v non-fat milk (Santa
Cruz) in TBS containing 0.1 % v/v Tween-20 (Fisher
Scientific; TBS-T). Membranes were incubated in the
indicated primary antibody (in 5 % milk/TBS-T) over-
night at 4 °C, washed 4x in TBS-T, incubated in
species-specific HRP-conjugated secondary antibody (in
5 % milk/TBS-T) for 1 h at room temperature, and
then washed 4x in TBS-T. Membranes were subse-
quently developed with ECL Western blotting substrate
(Pierce) using the Fujifilm LAS-3000 developer. Mem-
branes were washed 1x in TBS-T and stripped in low
pH stripping buffer [25 mM Glycine HCl, pH 2.0 and
1 % w/v SDS] to remove primary and secondary anti-
body, washed 3x in TBS-T, and blocked for 1 h (in
5 % milk/TBS-T) at room temperature before probing
with the next primary antibody. Integrated density of
immunoreactive spots was measured using MultiGauge
Software (FujiFilm) and normalized to % control (vehicle).
Generation, purification, and characterization of rabbit pAb
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A11 (anti-prefibrillar oligomers, 0.5 μg/ml), rabbit pAb
OC (anti-fibrillar oligomers and fibrils; 0.25 μg/ml) and
mouse mAb Nu-4 (anti-oligomers; 1 μg/ml) have been
described previously [28, 67]. Normalization to total
APP/Aβ signal was achieved by detection of human
APP transgene metabolites with the mouse mAb 6E10
(1:1000; Covance). Peroxidase-conjugated goat anti-rabbit
IgG (H + L; 1:20,000; Vector Labs) or goat anti-mouse
IgG (H+ L; 1:20,000; Vector Labs) were used for
detection. To quantify total Aβ levels, human/rat Aβ
1–40/1–42 ELISA kits (Wako) were used according to
the manufacturer’s instructions. Absolute concentrations
of total or oligomeric Aβ were normalized to initial
tissue weight prior to analysis.
Histology
Aβ was assessed via free-floating fluorescence immuno-
histochemistry using mAb 6E10 (1:1000, Covance,
Princeton, NJ). To assess Aβ deposition within vessels
sections were co-stained with collagen IV (1:300).
Briefly, sections were washed 3x in PBS for 10 min,
incubated in 3 % acetic acid for 10 min followed by
1 mg/ml Pepsin for 30 min. Following 1x in PBS/0.1 %
NaAz for 10 min and 3x 10 min washes in PBS, sections
were incubated 1 % H2O2 for 20 min, 3x further 10 min
washes in PBS before blocking with 5 % goat serum in
TBS/Triton-X for 1 h. Sections were then incubated with
mAb 6E10 (1:1000, Covance, Princeton, NJ) and collagen-
IV (1:300, Abcam ab6586) overnight at 4 °C. The follow-
ing day, sections were given 3x 20 min washes in PBS then
incubated with anti-mouse and anti-rabbit fluorescent
secondary antibodies (1:200, mouse Alexa Fluor 488 and
rabbit 594 respectively) at room temperature for 2 h. After
3x final 20 min washes in PBS, sections were mounted
and coverslipped with Vectashield (Vector Laboratories,
Inc., Burlingame, CA). Images were captured on an
Olympus BX61 upright microscope with an attached
Olympus DP71 camera.
Perls’s Berlin blue-stained clusters of hemosiderin
staining were evaluated from sections throughout the
neocortex, hippocampus, and thalamus. Briefly, sections
were mounted on slides and dried overnight. The next
days, slides were immersed in equal parts of 20 %
hydrochloric acid and 10 % potassium ferrocyanide for
20 mins. Slides were then washed 3x in dH20 then
counterstained with nuclear fast red for 5 min. Following
another 2x rinses in dH20, sections were dehydrated
through 95 % and 2x changes of 100 % ethanol. Sections
were then cleared in xylene, coverslipped and allowed to
dry overnight before imaging.
Statistical analyses
All data are presented as the mean ± s.e.m. Statistical
significance (P < 0.05) was determined using Student’s
t tests or one/two-way ANOVA with Bonferroni
posthoc analyses (GraphPad Prism, San Diego, CA).
Results
Glucose homeostasis and learning behavior were tested
in mice at 4-5 mo of age. Young male and female WT,
Sorcs1 -/-, APP/PSEN1 and Sorcs1 -/- x APP/PSEN1
mice had similar levels of fasting glucose and insulin
(Additional file 1: Figure S1a-d) and normal ability to
clear a glucose load when assessed by a GTT (Additional
file 1: Figure S1a,c). Fasting plasma glycerol (Additional
file 1: Figure S1i,k) and triglycerides (TG) (Additional
file 1: Figure S1j,l) levels were unaltered indicating
normal lipid homeostasis in mice of both sexes. Female
Sorcs1 -/- mice displayed lower body weight, shorter
body length, and reduced lean mass (Additional file 1:
Figure S1e,f,m) but comparable fat mass (Additional
file 1: Figure S1n) when compared to WT mice. Female
Sorcs1 -/- mice were also reduced in weight and lean
mass (Additional file 1: Figure S1e,m) as compared with
APP/PSEN1 mice. No differences in body weight or fat
mass were seen among male cohorts (Additional file 1:
Figure S1g,p). However, male Sorcs1 -/- mice were
shorter in length than APP/PSEN1 mice and Sorcs1 -/- x
APP/PSEN1 mice had reduced lean mass as compared
to WT mice (Additional file 1: Figure S1h,o). Crossing
Sorcs1 -/- with APP/PSEN1 mice did not promote the
onset of any metabolic phenotype in either female nor
male mice.
When behavior was assessed in Y-maze, both male
and female young Sorcs1 -/-, APP/PSEN1 and Sorcs1 -/-
x APP/PSEN1 mice all had worse SA memory perform-
ance than WT mice, with only Sorcs1 -/- x APP/PSEN1
reaching significance in the females and Sorcs1 -/- in the
males (Fig. 1a-b). Memory was also assessed in the novel
object recognition (NOR) test, both male and female
WT mice had intact memory whereas male and female
Sorcs1 -/-, APP/PSEN1, and Sorcs1 -/- x APP/PSEN1
mice were all impaired and to a comparable degree
(Fig. 1c-d).
In order to determine whether cohorts in this study
were susceptible to the induction of metabolic dysregu-
lation by high fat feeding, a commonly used metabolic
stressor to unveil a metabolic phenotype, all mice were
placed on a 60 % high fat diet (HFD) for 4 weeks. All
female mice were resistant to diet-induced perturbations
in glucose homeostasis (Fig. 2a) with no genotype-
dependent differences in fasting plasma metabolic pa-
rameters detected at 7 mo of age, consistent with the
notion that female sex is protective against a metabolic
phenotype (Fig. 2d-e, h-I,l). After 4 weeks of HFD feed-
ing, differences in body weight observed on regular
chow were no longer statistically significant (Fig. 2m).
As noted above for regular chow feeding, female
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Sorcs1 -/- mice on HFD continued to have less lean
mass than WT or APP/PSEN1 mice (Fig. 2p). While
all mice gained a significant amount of fat mass on
HFD, body composition analysis revealed no differ-
ences among cohorts (Fig. 2q).
After 4 weeks on HFD and in comparison to WT mice
at baseline (4-5 mo of age), male APP/PSEN1, Sorcs1 -/-,
and Sorcs1 -/- x APP/PSEN1 mice displayed impaired glu-
cose tolerance (Fig. 2b) and APP/PSEN1 and Sorcs1 -/- x
APP/PSEN1 mice impaired insulin sensitivity (Fig. 2c).
Unexpectedly, APP/PSEN1 male had worse glucose
tolerance and insulin sensitivity than Sorcs1 -/- x APP/
PSEN1 mice (Fig. 2b-c). Insulin sensitivity was also worse in
APP/PSEN1 mice than in Sorcs1 -/- mice (Fig. 2c). This
was also reflected in higher levels of fasting plasma
insulin in male APP/PSEN1 mice compared to all
other groups (Fig. 2f ). All other metabolic parameters
were unaltered (Fig. 2g, j-k, n) as was body weight
(Fig. 2o) and lean mass (Fig. 2r). As with females, all
males gained a significant amount of fat mass on the
HFD as seen by body composition analyses (Fig. 2s).
These data are consistent with enhanced susceptibility
to HFD induced metabolic dysregulation of APP/
PSEN1 mice (Ruiz et al., in press [56]).
Fig. 1 Female but not male Sorcs1 -/- x APP/PSEN1 mice display impaired memory. Spontaneous alternation (SA) was assessed at 5 mo (a, b) and re-
tested again at 9 mo (e, f), while novel object recognition (NOR) was assessed at 5 mo (c, d) in cohorts of male and female WT (n = 11–14/group),
Sorcs1 -/- (n = 15–16/group), APP/PSEN1 (n = 6–11/group) and Sorcs1 -/- x APP/PSEN1 (n = 9/group). One-way ANOVA with Bonferroni posthoc analyses;
*P < 0.05, **P < 0.01 and ***P < 0.001. Data expressed as mean ± s.e.m
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Aging is a risk factor for both AD and T2D. To deter-
mine whether cohorts were more susceptible to aging-
induced insulin resistance and/or glucose intolerance,
mice were maintained on the HFD for an additional
8 weeks i.e., to a total of 12 weeks on HFD. During this
extension of HDF feeding, abnormalities in glucose
homeostasis emerged in females cohorts. Both female
APP/PSEN1 and Sorcs1 -/- x APP/PSEN1 mice displayed
impaired glucose tolerance (Fig. 3a), and APP/PSEN1
mice displayed impaired insulin sensitivity (Fig. 3b). The
metabolic phenotype was more severe in female APP/
PSEN1 and Sorcs1 -/- x APP/PSEN1 mice than in female
Sorcs1 -/- mice (Fig. 3a-b). After 12 weeks of HFD,
fasting plasma insulin levels were elevated in all geno-
type groups but this elevation only reached statistical
significance in female APP/PSEN1 mice (Fig. 3e). All
other metabolic parameters were unaltered (Fig. 3f, i, j,
m) across other cohorts. Sorcs1 -/- mice had lower body
weight than WT and APP/PSEN1 mice (Fig. 3n).
Male APP/PSEN1, Sorcs1 -/-, and Sorcs1 -/- x APP/
PSEN1 mice continued to display impaired glucose
tolerance (Fig. 3c) compared to WT mice. Interestingly,
the reduced insulin sensitivity in male mice observed
after 4 weeks HFD and noted above was less severe after
12 weeks of HFD (Fig. 3d). In all groups, maintenance on
HFD was associated with increased fasting plasma insulin
levels; however, the elevated plasma insulin level previ-
ously observed in male APP/PSEN1 mice was no longer
obvious because the plasma insulin levels in other groups
were now similarly increased (Fig. 3g). All other metabolic
Fig. 2 After 4 weeks high fat feeding, male but not female APP/PSEN1, Sorcs1 -/- and Sorcs1 -/- x APP/PSEN1 mice demonstrate impaired
glucose homeostasis compared to WT mice. Glucose tolerance testing (a-b), insulin tolerance testing (c) fasting plasma insulin (d, f), fasting
plasma glycerol (e, g), fasting plasma non-esterified free fatty acids; NEFA (h, j), fasting plasma triglycerides (i, k), fasting plasma branched-chain amino
acids; BCAA (l, n) body weight (m, o), lean mass (p, r) and fat mass (q, s) in cohorts of male and female WT (n = 5–12/group), Sorcs1 -/- (n = 10–16/
group), APP/PSEN1 (n = 6–7/group) and Sorcs1 -/- x APP/PSEN1 (n = 4–9/group). Cohorts were maintained on standard rodent chow from weaning until
6 mo when they were placed on a 60 % high fat diet for 4 weeks. a-c two-way ANOVA with Bonferroni posthoc analyses; *P < 0.05, **P < 0.01 and
***P < 0.001 green = Sorcs1 -/- versus WT, blue = APP/PSEN1 versus WT, red = Sorcs1 -/- x APP/PSEN1 versus WT, #P < 0.05 blue = APP/PSEN1 versus Sorcs1
-/- x APP/PSEN1, &P < 0.05 blue = Sorcs1 -/- versus APP/PSEN1. d-s one-way ANOVA with Bonferroni posthoc analyses; *P < 0.05 and **P < 0.01. Data
expressed as mean ± s.e.m
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parameters were unaltered (Fig. 3h, k-l, o) as was body
weight (Fig. 3p) when compared across other cohorts.
When learning behavior was re-tested after 12 weeks
on HFD, all groups of female mice (regardless of WT vs
genetically manipulated) displayed similar performance
(Fig. 1e). As observed at baseline and as mentioned
above, male Sorcs1 -/- mice had poorer performance
than WT mice in SA memory (Fig. 1f ). No other groups
of male mice displayed learning behavior deficits that
reached statistical significance.
After 12 weeks of HFD feeding, mice were sacrificed
to determine whether Sorcs1 deficiency exacerbated
brain Aβ accumulation. Sorcs1 -/- x APP/PSEN1 mice
displayed similar levels of total brain Aβ40 (Fig. 4a-f ),
Aβ42 (Fig. 4 g-l), Aβ42/40 ratio (Fig. 4m-r) and Aβ
oligomers (Fig. 4s-x) compared to APP/PSEN1 mice in
both male and female cohorts. Similarly, no differences
in Aβ plaque load were detected between the two geno-
types (Fig. 4y). Notably, females had much higher levels
of insoluble Aβ in the formic acid fraction than males.
As expected due to the absence of human Aβ, no
plaques were observed in either male or female WT and
Sorcs1 -/- mice (data not shown). Interestingly, Aβ was
deposited as cerebral amyloid angiopathy (CAA) in large
and small blood vessels within the brains of male and
female APP/PSEN1 mice as well as Sorcs1 -/- x APP/
PSEN1 mice (Fig. 5). Quantification of CAA is challenging
at best, but, at the qualitative level, male and female Sorcs1
-/- x APP/PSEN1 mice appeared to have less vascular Aβ
than APP/PSEN1 mice and when present was confined to
large vessels (Fig. 5). Microhemorrhages were also detect-
able within the brains of all cohorts (Fig. 6). As observed
with the CAA, the brains of both male and female APP/
PSEN1 mice appeared to display more cerebral micro-
hemorrhages than WT mice, and the brain microhemor-
rhage count was less in Sorcs1 -/- X APP/PSEN1 mice
than in APP/PSEN1 mice. Unexpectedly, the microhemor-
rhage count in Sorcs1 -/- mice was similar to that of
Sorcs1 -/- X APP/PSEN1 mice despite the absence of
human Aβ or CAA in Sorcs1 -/- mice.
a b c d
e f g h
i j k l
m n o p
Fig. 3 After 12 weeks high fat feeding, female Sorcs1 -/- x APP/PSEN1 mice demonstrate greater impairment in glucose intolerance and insulin
sensitivity than Sorcs1 -/- mice. Glucose tolerance testing (a, c), insulin tolerance testing (b, d) fasting plasma insulin (e, g), fasting plasma glycerol
(f, h), fasting plasma non-esterified free fatty acids; NEFA (i, k), fasting plasma triglycerides (j, l), branched-chain amino acids; BCAAs (m, o) and
body weight (n, p) in cohorts of male and Female WT (n = 5–12/group), Sorcs1 -/- (n = 10–16/group), APP/PSEN1 (n = 6–7/group) and Sorcs1 -/- x
APP/PSEN1 (n = 4–9/group). Cohorts were maintained on standard rodent chow from weaning until 6 mo when they were placed on a 60 % high
fat diet for 12 weeks. a-d two-way ANOVA with Bonferroni posthoc analyses; *P < 0.05, **P < 0.01 and ***P < 0.001 green = Sorcs1 -/- versus WT,
blue = APP/PSEN1 versus WT, red = Sorcs1 -/- x APP/PSEN1 versus WT, #P < 0.05 and ##P < 0.01 red = Sorcs1 -/- versus Sorcs1 -/- x APP/PSEN1, &&P <
0.01 and &&&P < 0.001 blue = Sorcs1 -/- versus APP/PSEN1. e-p one-way ANOVA with Bonferroni posthoc analyses; *P < 0.05. Data expressed
as mean ± s.e.m
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Discussion
Multiple epidemiological studies have demonstrated an
association between insulin resistance and T2D and
increased risk for cognitive impairment in humans [4,
13, 34, 62]. SORCS1 has been associated with both T2D
and AD. Furthermore, the human linkage to SORCS1 is
stronger for women in both T2D and AD. Here, we
tested the hypothesis that a mouse model with a
compound proamyloidogenic/prodiabetogentic genotype
might be useful in studying how the two conditions
y
a b c d e f
g h i j k l
m n o p q r
s t u v w x
Fig. 4 APP/PSEN1 and Sorcs1 -/- x APP/PSEN1 have similar levels of Aβ as well as plaque load within the brain. Hemibrains of male and female
APP/PSEN1 (n = 5–12/group) and Sorcs1 -/- x APP/PSEN1 (n = 10/group) mice were processed via differential detergent solubilization to produce
fractions of TBS-soluble, Triton-X-soluble and formic-acid soluble Aβ. Levels of Aβ 40 (a-f) and Aβ 42 (g-l) were determined from each fraction via
ELISA. Total Aβ equals the sum of Aβ from each fraction. The Aβ42/40 ratio was calculated for each fraction (m-r). Oligomeric Aβ was assessed
from the TBS-soluble fraction via dotblot analyses using OC (s, v), A11 (t, w) and NU-4 (u, x) antibodies. 6E10 positive Aβ plaque load was assessed via
immunohistochemistry within the cortex and hippocampus (y) of male and female APP/PSEN1 and Sorcs1 -/- x APP/PSEN1 mice (n = 2-3/group). a-x
P > 0.05, Student’s t-tests. Data expressed as mean ± s.e.m. y scale bar = 1 mm
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coexist with possible bidirectional exacerbation (i.e., that
cerebral amyloidosis exacerbated glucose intolerance
and vice versa). In order to test this hypothesis, we
assessed longitudinal aging-related memory behavior,
glucose homeostasis, and Aβ pathology in both male
and female WT, Sorcs1 -/-, APP/PSEN1 and Sorcs1 -/-
mice crossed with APP/PSEN1 mice.
In the present study we demonstrate that when
young, both male and female Sorcs1 -/-, APP/PSEN1
and Sorcs1 -/- x APP/PSEN1 mice display normal
glucose homeostasis. This fits with previous studies
that have shown that young APP/PSEN1 mice have
similar glucose tolerance to WT mice when fed a
standard diet [17]. At this age, crossing Sorcs1 -/- mice
with APP/PSEN1 did not precipitate earlier onset of
metabolic dysfunction in either males or females. Inter-
estingly, young female Sorcs1 -/- displayed lower body
weight, shorter body length and reduced lean mass
when compared to WT mice. Female Sorcs1 -/- mice
were also shorter in length than APP/PSEN1 and Sorcs1
-/- x APP/PSEN1 had reduced lean mass compared to
WT mice. This is the first study to report such differ-
ence and the cause is unknown. Lean mass is important
for insulin action and metabolic control in that it has
salutary effects. If two mouse models have the same
metabolic flexibility but one has a higher lean mass,
one can argue that the beneficial effects of higher lean
mass could offset disturbances in metabolic flexibility.
When behavior was assessed in the Y-maze, the Sorcs1 -/-
mice X APP/PSEN1 cross was associated with significantly
impaired learning behavior in the females and trend for
worse performance in Sorcs1 -/- and APP/PSEN1 mice, al-
though this did not reach statistical significance. In males,
all cohorts had a worse performance in the Y-maze than
WT mice but only Sorcs1 -/- were significantly impaired.
When behavior was re-assessed in the females, cohorts
were no longer significantly different, the reason for this
appears to be the worsening of memory in the WT group,
the reason for this is unknown but could possibly due to
the high fat diet, or age related decline, rather any change
in the other cohorts which were already poor. In the male
cohort, the Sorcs1 -/- mice continue to be impaired when
compared to WT mice. When NOR was assessed, both
male and female WT mice displayed intact learning behav-
ior whereas male and female mice of Sorcs1 -/-, APP/
PSEN1 and Sorcs1 -/- x APP/PSEN1 genotypes were all
impaired. This is the first study to demonstrate learning
deficits in Sorcs1 -/- or Sorcs1 -/- x APP/PSEN1 mice.
Unexpectedly in the present study both male and female
APP/PSEN1 mice and Sorcs1 -/- mice displayed very early
onset learning behavior deficits in NOR. For this reason,
the NOR test was not repeated at later time points.
Fig. 5 APP/PSEN1 and Sorcs1 -/- x APP/PSEN1 mice display vascular Aβ within the brain. Aβ was detectible within cerebral blood vessels of male
and female APP/PSEN1 and Sorcs1 -/- x APP/PSEN1 mice (n = 2–3/group) when assessed via immunohistochemistry using 6E10 and collagen IV.
Data expressed as mean ± s.e.m. Scale bar = 200 μm
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Overall, the behavioral data for the Y-maze and NOR for
both genders trend in the same direction for the most
part. We cannot discount that lack of significance between
some groups may be due to lack of power or sensitivity of
these tests at the time points tested. Additional studies are
required to dissect the temporal onset of NOR deficits in
the Sorcs1 -/- x APP/PSEN1 mice and any potential sex
differences in Y-maze.
In order to deliver a metabolic stress to unveil a meta-
bolic phenotype, APP/PSEN1 mice have previously been
placed on either a high fat diet or crossed with transgenic
models of obesity and/or diabetes. When we placed mice
on a 60 % HFD, we found that male APP/PSEN1, display
evidence of transient elevated fasted plasma insulin as well
as both glucose intolerance and insulin insensitivity. Dur-
ing the development of T2D, β-cells initially compensate
for insulin resistance by increasing the amount of insulin
in circulation. This is consistent with previous studies
where APP/PSEN1 mice have increased fasted insulin,
develop glucose intolerance and become less insulin
sensitive when placed on a HFD [9, 35, 52, 70]. These re-
sults demonstrate that APP/PSEN1 mice are susceptible
to metabolic impairment on a HFD, consistent with a
predisposition for the development of diabetes. Male
Sorcs1 -/- and Sorcs1 -/- x APP/PSEN1 displayed impaired
glucose tolerance when compared to WT mice. Unexpect-
edly, metabolic abnormalities in male Sorcs1 -/- mice were
not exacerbated when crossing this line with the APP/
PSEN1 mouse. Indeed, there was a clear trend for Sorcs1
deficiency to mitigate APP/PSEN1 phenotypes. In general,
the metabolic phenotype in the Sorcs1 -/- line was much
milder than expected, especially when compared to the
APP/PSEN1 line.
The female mice in the present study were resistant to
metabolic abnormalities when placed on the diet for
only 4 weeks. It is well known that female mice are re-
sistant to metabolic effects of a high fat diet, which may
account for their delayed onset of metabolic dysfunction
when compared to males here. Petterson et al. [44]
showed that in response to a high fat diet, plain C57Bl/6
male but not female mice developed hyperinsulinemia,
hypotrophic islets, low grade systemic inflammation and
an increased macrophage population in their intra-
abdominal adipose tissue. In contrast, female mice had
an elevated anti-inflammatory regulatory T cell popula-
tion in their adipose tissue [44]. In the present study,
after 12 weeks of HFD, female APP/PSEN1 mice displayed
metabolic abnormalities and increased fasted plasma insu-
lin levels. Both female APP/PSEN1 and Sorcs1 -/- x APP/
PSEN1 mice had impaired glucose tolerance and APP/
Fig. 6 APP/PSEN1 and Sorcs1 -/- x APP/PSEN1 mice display micro-hemorrhages within the brain. Perl’s blue positive micro-hemorrhages were
seen within the brains of cohorts of all male and female WT, Sorcs1 -/-, APP/PSEN1 and Sorcs1 -/- x APP/PSEN1 (n = 2–4/group) when
assessed via immunohistochemisty. P > 0.05, Student’s t-tests. Data expressed as mean ± s.e.m. Scale bar = 200 μm
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PSEN1 mice had impaired insulin sensitivity. Unlike
males, the female Sorcs1 -/- x APP/PSEN1 had signifi-
cantly worse glucose tolerance and insulin sensitivity than
female Sorcs1 -/- mice. The lack of deficit in glucose
tolerance in males between Sorcs1 -/- x APP/PSEN1
and Sorcs1 -/- is most likely due to the latter showing
a significant deficit less visible in the females.
While APP/PSEN1 overexpression facilitated glucose
dysregulation, despite differences in glucose metabolism
seen between Sorcs1 -/- and Sorcs1 -/- x APP/PSEN1
after 12 weeks of HFD, unexpectedly, Sorcs1 -/- crossed
onto APP/PSEN1 mice did not modulate brain Aβ levels
or oligomer levels beyond the changes already induced
by the APP and PSEN1 mutations. The unexpected lack
of worsening of pathology in the Sorcs1 -/- x APP/
PSEN1 mice may indicate that Aβ deposition may be the
cause rather than the effect of alterations in glucose
metabolic observed. In support of this formulation, we
have previously described the appearance of metabolic
inflexibility in APP/PSEN1 mice following high fat
feeding (Ruiz et al., in press [56]). In the present study,
Aβ levels were measured from whole forebrain extracts;
therefore, we cannot exclude possible subtle changes in
regional Aβ levels relevant to memory behavior (such
as the hippocampus and entorhinal cortex) and/or
regulation of energy balance (the hypothalamus). Future
studies would need to pick apart regional Aβ response
and hypothalamic insulin signaling in Sorcs1 -/- and
Sorcs1 -/- x APP/PSEN1 mice. We cannot also exclude
potential subtle changes in endogenous murine Aβ levels
as have previously shown that female Sorcs1 -/- mice
have elevated endogenous murine levels compared to
WT mice [29]. Previously, Reitz et al. [53] reported that
genetic variants in SORCS1 are associated with increased
risk of AD and that over-expression of SorCS1 reduces
Aβ levels and γ-secretase activity, whereas suppression
of SorCS1 increases Aβ levels and APP processing by
γ-secretase activity. Unexpectedly, however, ablation of
Sorcs1 in the present study impacted memory without
affecting production/accumulation of whole brain levels
of Aβ. Although we can’t discount subtle altered levels
of endogenous murine Aβ in Sorcs1 -/- mice as we have
previously reported [29] nor changes in regional Aβ
as discussed above, there may be other more generalized
effects that SORCS1 may have on memory and neuro-
degeneration. Prominent neuronal expression of the
Vps10p-domain sorting receptor family, of which SORCS1
is a member, has resulted in recent data supporting their
role in neuronal activity, plasticity related processes and
neurogenesis [53]. Furthermore, several studies have
demonstrated links between SNPs in SORCS1 and cogni-
tion. Printy et al. [49] assessed atrophy profiles against
genetic markers in the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) cohort, finding associations of cerebral
atrophy with SNPs on APP but also ventricular enlarge-
ment with SNPs on SORCS1. Reitz et al. [53] also assessed
the impact of genetic variation in SORCS1 and memory
retention and found three SNPS were associated with
memory retention.
Studies in other systems examining the relationship
between AD pathology and diabetes have yielded vari-
able results. One study revealed no association of the
two pathologies [16]. In another study, cerebral amyloid-
osis was only exacerbated in diabetics carrying the APOE
ε4 allele [43], while in another, the result was that AD
pathology was reduced among diabetics [7]. Interest-
ingly, one of these studies also showed that the com-
bined effects of carrying the ε4 allele and being diabetic
increased the risk for a dementia that was clinically
classified as vascular dementia [43]. Previous studies
have also shown an association between both diabetes
and vascular dementia [27, 30, 42]. More recently,
Arvanitakis et al. [3] found that diabetes was associated with
increased risk of brain infarction but not AD pathology in
older individuals. At a recent workshop on AD and T2D at
the US National Institutes of Health, the consensus was
that the clinical cognitive decline in diabetics was probably
more attributable to vascular dementia (Stoeckel, Gandy,
and Arvanitakis, manuscript in preparation).
In the present study we assessed vascular Aβ, finding
Aβ in blood vessels within the brains of both male and
female APP/PSEN1 mice as well as Sorcs1 -/- x APP/
PSEN1 mice. Qualitative assessment revealed that both
male and female APP/PSEN1 mice displayed abundant
deposits of Aβ in both large and small caliber vessels.
Female Sorcs1 -/- x APP/PSEN1 mice appeared to have
less vascular Aβ than APP/PSEN1 mice and, when
present, CAA was restricted to large caliber vessels.
Male Sorcs1 -/- x APP/PSEN1 appeared to display
relatively less vascular Aβ, and, again when present was
restricted to large vessels. It is possible that reduced
CAA could be a marker of altered Aβ trafficking and/or
clearance, which should be an area of interest in future
study. We also assessed microhemorrhages, and bleeds
were detected in all mice assessed after HFD. Microhe-
morrhage in the WT mice is consistent with increased
risk of hemorrhagic strokes associated with poor diet
and obesity [45]. Both male and female APP/PSEN1
mice tended toward greater numbers of bleeds than WT
mice. This is consistent with previous studies that have
shown that APP/PSEN1 mice are prone to vascular
alterations, which are exacerbated on a HFD [52]. Both
male and female Sorcs1 -/- mice revealed more bleeds
than WT mice.
The extent to which dementia in humans is due to AD
rather than to vascular dementia is an area of great
interest, and the pathology of dementia in T2D is usually
mixed [1, 43]. Human studies have yielded a range of
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results, with some, but not all, linking cerebral amyloid-
osis to insulin resistance [68]. Mouse models have been
similarly variable. When APP mice are crossed with the
leptin-deficient ob/ob model they showed no change in
Aβ burden, however both amyloid angiopathy and angii-
tis were increased together with exacerbated cognitive
dysfunction [66], while in contrast when Tg2576 mice
are crossed with Irs2-/- insulin resistant mice show
reduced Aβ pathology and cognitive improvement [24].
Recently, Ramos-Rodriguez et al. [51] crossed APP/
PSEN1 mice with the with the morbidly obese and
diabetic db/db model, finding fewer plaques, a shift in
soluble/insoluble pool of Aβ, increased microglia activa-
tion and increased hemorrhage burden in the crossed
mice. Niedowicz et al. [38] also crossed APP/PSEN1
mice with db/db mice, finding that the crossed mice
displayed extreme obesity, diabetes and parenchymal Aβ
deposition with strikingly severe cerebrovascular path-
ology of aneurysms and small strokes. As with the
present study, the crossed mice in the Niedowicz study
did not develop elevated levels of Aβ deposition. The
crossed mice had more impairment in learning behavior
in the Morris water maze than db/db or APP/PSEN1
alone. Neither the crosses of Ramos-Rodriguez [51] nor
those of Niedowics [38] predicted the results that we
observed wherein the diabetogenic mutant mitigated the
phenotype of the AD model.
Previous studies in diabetic models have documented
increased angiogenesis and arteriogenesis, consisting of
immature, unstable blood vessels leading to increased
permeability of the blood–brain barrier [32, 38, 47, 48].
In the present study, we found evidence of both vascular
Aβ and microhemorrhages, however, Sorcs1 -/- x APP/
PSEN1 mice did not display an exacerbated phenotype;
if anything, there was a trend toward reduced vascular
Aβ and hemorrhage load in the Sorcs1 -/- x APP/PSEN1
mice when compared with the APP/PSEN1 mice. Simi-
larly, a recent study in which diabetes was induced in
APP/PSEN1 mice using streptozotocin treatment
documented reduced amyloid angiopathy when com-
pared to sham controls. This was associated with a slight
reduction in plaque load and increased microglial activa-
tion [50]. In the case of the genes and models that we
have studied, we tentatively conclude that metabolic
abnormalities in female Sorcs1 -/- x APP/PSEN1 mice
are not linked to changes in Aβ metabolism nor in brain
bleeds; however, further detailed quantitative investiga-
tion of the vasculature in this model would be required
to establish this proposed conclusion. The role of
inflammation in the Sorcs1 -/- x APP/PSEN1 mice also
requires further investigation.
In accordance with the present study, Kebede et al.
[23] assessed the metabolic profile of female Sorcs1 -/-
mice over time, finding that without intervention they
do not develop diabetes. Glucose intolerance was
apparent in Sorcs1 -/- mice tested at 20 weeks of age. As
with the present study, no mutation-related differences
in fasted plasma insulin were observed up to 18 weeks.
No abnormality in insulin sensitivity was detected at
12 weeks. The authors went on to place the Sorcs1 -/-
mice on a HFD, and, while they saw trends toward
elevated glucose levels in response to a GTT, the trends
were not significant. When Kebede et al. [23] crossed
the female Sorcs1 -/- mice with the leptin-deficient
model of obesity (ob/ob), the crossed mice went on to
develop diabetes, with elevated levels of fasting glucose
and insulin as well as impaired glucose tolerance and
sensitivity. On top of a diabetic phenotype, Sorcs1
deficiency in the ob/ob model lead to severe depletion of
insulin granules in pancreatic β-cells, leading the authors
to suggest that Sorcs1 is involved in vesicular trafficking
and possibly biogenesis of insulin granules. As with the
present study, the metabolic phenotype of Sorcs1 -/-
mice as characterized by Kebede et al. [23] required
genetic or diet-induced obesity to be triggered. There-
fore, as with the unexpectedly mild metabolic and
amyloidosis phenotypes of Sorcs1 -/- x APP/PSEN1 mice
as opposed to the exacerbated phenotypes of other
combined diabetic/cerebral amyloidotic mouse models,
the APP/PSEN1 transgenes were apparently less stressful
to beta cells and/or insulin action when compared to the
metabolic stress induced by db/db. Previous studies
show that the combination of a genetic proamyloido-
genic phenotype and potentially diabetogenic phenotype
(induced by either drug, diet, or genetic manipulations)
can lead to exacerbation of either the proamyloidogenic
component of the phenotype, the prodiabetogenic
component of the phenotype, or exacerbation of both
components of the phenotype [8, 18, 20, 38, 46, 51, 52,
66]. Unexpectedly, not only did the two genetic lesions
not exacerbate each other in the present study, the
Sorcs1 deficiency tended to partially correct the diabeto-
genic phenotype of the APP/PSEN1 mice. It is worth
noting that “bidirectional exacerbation” is not uni-
versally observed, since Murakami et al. [37] reported
that insulin receptor mutation-induced insulin resistance
failed to exacerbate an Alzheimer’s-like phenotype in
mice. Thus, while our experience is in the minority, our
observations of no bidirectional exacerbation are not
singular.
Kebede et al. [23] have demonstrated that stressing
Sorcs1-/- mice by crossing with db/db is required to
reveal the islet failure phenotype. The formulation for
the basis of that model is that missorting and misproces-
sing of insulin constitutes the underlying pathogenesis.
Our data would suggest that the APP/PSEN1 proamyloi-
dogenic phenotype is not sufficiently metabolically
stressful to cause islet failure. This is our qualitative
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explanation for the non-exacerbation of the metabolic
phenotype. Our formulation for the mechanism by
which Sorcs1-/- modulates Aβ generation involves retro-
mer dysfunction and promotion of generation of the
pool of Aβ that arises from wildtype APP. For wildtype
APP, 75 % of secreted Aβ is generated by endosomes
and 25 % is generated in the trans Golgi network
(TGN). However, when the substrate is Swedish mutant
APP (i.e., APPKM670/671NL), the compartmental stoi-
chiometry is altered, such that 75 % of secreted Aβ derived
from Swedish APP is generated in the TGN and only 25 %
is generated in the endosome. We would propose that
Sorcs1-/-, by disrupting protein sorting in the TGN-
endosomal system, reduces access of TGN BACE (β-APP
sorting enzyme) to Swedish APP, thereby partially revers-
ing the proamyloidogenic phenotype.
Conclusions
In the present study we assessed memory, glucose homeosta-
sis, and brain biochemistry and pathology in male and female
WT, Sorcs1 -/-, APP/PSEN1, and Sorcs1 -/- X APP/PSEN1
mice. Male mice with either the APP/PSEN1 or Sorcs1 -/-
genotype displayed earlier onset and persistent impairment
in both glucose homeostasis and in learning behavior. Unlike
prior examples in the literature, the behavioral and metabolic
abnormalities in male mice were not exacerbated when the
two disease model mice (Sorcs1 -/- models T2D; APP/PSEN1
models AD) were crossed. In contrast to the male Sorcs1 -/-
X APP/PSEN1 mice, female Sorcs1 -/- X APP/PSEN1 mice
showed later onset but worse metabolic dysfunction than
Sorcs1 -/- knockout mice and worse memory than WT mice.
The deletion of Sorcs1 from APP/PSEN1mutant mice led to
no obvious changes in brain levels of total or oligomeric Aβ
peptide. In general, unexpectedly, there was a trend for gene
targeting of Sorcs1-/- to mitigate, not exacerbate, the meta-
bolic, behavioral, and amyloid pathologies. Mixed pathology
is a feature of some – perhaps most – late life dementia,
raising the likelihood that compound genotypes may be
required in order to approximate the pathology in mice,
these results indicate that compound genotypes of highly
complex diseases (such as AD plus T2D) may yield
unexpected phenotypes that limit their utility.
Additional file
Additional file 1: Figure S1. Young Sorcs1 -/-, APP/PSEN1 mice and
Sorcs1 -/- x APP/PSEN1 mice display normal glucose homeostasis.
Glucose tolerance testing (a,c), fasting plasma insulin (b,d), body
weight (e,g), body length (f,h), fasting plasma glycerol (i,k), fasting
plasma triglycerides (j,l), lean mass (m,o) and fat mass (n,p) in cohorts
of male and female WT (n = 5- 8/group), Sorcs1 -/- (n = 10/group),
APP/PSEN1 (n = 4-8/group) and Sorcs1 -/- x APP/PSEN1 (n = 4- 6/
group). Cohorts were maintained on standard rodent chow from
weaning and assessed at 4-5 months of age. *P < 0.05, **P < 0.01 and
***P < 0.001; One-way ANOVA with Bonferroni posthoc analyses. Data
expressed as mean ± s.e.m. (PDF 350 kb)
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